Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
6.75
-0.08 (-1.17%)
Apr 29, 2026, 3:04 PM CST
4.81%
Market Cap 6.93B
Revenue (ttm) 623.64M
Net Income (ttm) -347.20M
Shares Out 1.03B
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend 0.02 (0.29%)
Ex-Dividend Date Jul 4, 2025
Volume 50,995,352
Average Volume 116,974,636
Open 7.12
Previous Close 6.83
Day's Range 6.63 - 7.12
52-Week Range 5.47 - 9.40
Beta 0.10
RSI 42.68
Earnings Date Apr 29, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen... [Read more]

Sector Healthcare
Founded 1994
Employees 889
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.

Financial Statements

News

There is no news available yet.